Results 61 to 70 of about 96 (70)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

Frontiers in Pharmacology
Objectives: This study aims to investigate adverse events (AEs) and adverse drug reactions (ADRs) associated with pirfenidone and nintedanib, two antifibrotic drugs used to treat idiopathic pulmonary fibrosis (IPF).Methods: Reporting odds ratio (ROR) and
Menglin He, Taoran Yang, Jian Zhou, Rurong Wang, Xuehan Li   +4 more
doaj   +1 more source

Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess

Frontiers in Pharmacology
IntroductionAnti-EGFR monoclonal antibodies (mAbs)--cetuximab, panitumumab, and necitumumab--are cornerstone therapies for selected solid tumors but are frequently associated with cutaneous adverse drug reactions (ADRs).
Natalia Sauer, Piotr Giedziun, Jacek Calik, Jacek Calik, Anna Wiela-Hojeńska   +4 more
doaj   +1 more source

Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study

Therapeutic Advances in Drug Safety
Background: Anti-β-amyloid monoclonal antibodies provide a disease-modifying treatment approach for Alzheimer’s disease, but post-marketing safety concerns remain, particularly amyloid-related imaging abnormalities (ARIA).
Wei-Yang Xue, Xi Li, Wen-Ting Li, Bao-Zhi Qin, Cong-Zhi Wang, Tao Liu, Min Wang   +6 more
doaj   +1 more source

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess

Frontiers in Pharmacology
IntroductionEnfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy.
Yuanbin Huang, Meiqi Xu, Xinmiao Ma, Wei Wang, Chen Shen, Fei Liu, Zhiqi Chen, Jiawen Wang, Qian Guo, Xiancheng Li   +9 more
doaj   +1 more source

Characterization of adverse reactions to four common targeted drugs for hepatocellular carcinoma in WHO-VigiAccess

Scientific Reports
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality, with limited therapeutic options available for advanced stages of the disease.
Zeyu Wang, Jiyao Sheng, Xuewen Zhang
doaj   +1 more source

Adverse drug reaction profiles of histone deacetylase inhibitors

Scientific Reports
The safety and tolerability of histone deacetylase inhibitors (HDACIs) were always a matter of concern. This study aimed to explore the global observational adverse drug reaction (ADR) profiles of the HDACIs: vorinostat, belinostat, panobinostat ...
Ruqayyah Begum, Jason L. Parsons, Alan M. Jones   +2 more
doaj   +1 more source

Correction: Comparative real-world safety profiles of caspofungin, micafungin, and anidulafungin: a disproportionality analysis based on FAERS and VigiAccess databases

Frontiers in Pharmacology
Jingxiu Chen, Chunhua Chen, Xiaobin Lin, Jiajia Yan, Yifan Zheng, Yifan Zheng, Pan Chen, Jia Li, Jia Li   +8 more
doaj   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database

Pharmacological Research, 2017
Maria Del Zompo, Claudia Pisanu, Alberto Bocchetta   +2 more
exaly  

Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases

Expert Opinion on Drug Safety
Mandeep Kumar Arora, Atul Khurana
exaly  

Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases

Expert Opinion on Drug Safety
exaly